Myths vs facts: ApoB and longevity

ApoB (apolipoprotein B) is the core protein of atherogenic lipoproteins (LDL, VLDL, Lp(a)). Fact: Strong human evidence from prospective cohorts and Mendelian randomization shows that ApoB is a superior predictor of cardiovascular events compared to LDL cholesterol alone. Elevated ApoB drives atherosclerosis and reduces lifespan. Myth: ApoB is a direct 'longevity marker.' In reality, it is a risk factor – low ApoB correlates with lower cardiovascular risk, but longevity is multifactorial (genetics, lifestyle, inflammation). Some commercial tests oversimplify: a single ApoB value without context (age, sex, Lp(a), inflammation) is insufficient. Evidence is human-strong, but interpretation requires clinical judgment. Caveat: Lowering ApoB with statins or PCSK9 inhibitors improves outcomes, but not everyone benefits equally. For MyBody-X: The test can measure ApoB, but clinical decisions should be based on overall risk assessment.